Taiho Pharmaceutical Co. Ltd. and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) are each pumping $30 million into new VC firm Remiges Ventures to get more exposure to early stage research.

According to a July SEC filing, Remiges has raised $70 million of the targeted $150 million for its debut fund, Remiges BioPharma Fund L.P. The new firm is headed by Taro Inaba, who is managing director, and Walter Olesiak, who is a